MUHAMMAD AKRAM KHAN, M.D., M.B.A., F.A.C.C., F.S.C.A.I. 4201 MEDICAL CENTER DRIVE, SUITE 380, MCKINNEY, TX 75069 Office: 972-529-6939 Fax: 972-529-6935
EDUCATION:
POSTGRADUATE TRAINING: 2011-2013 Physician Executive MBA UT Southwestern Medical Center at UTD Richardson, Texas
1996-97 Fellowship in Interventional Cardiology Baylor University Medical Center Dallas, Texas
1993.96 Fellowship in Cardiology Baylor University Medical Center Dallas, Texas
1991.93 Residency in Medicine Wayne State University Medical Center Detroit, Michigan
1990.93 Internship in Medicine Wayne State University Medical Center Detroit, Michigan
MEDICAL SCHOOL: 1982-89 Dow Medical College Karachi, Pakistan – M.B.B.S.
COLLEGE: 1979-81 St. Patrick’s College Karachi, Pakistan
HOSPITAL/ACADEMIC APPOINTMENTS: July 2013 Laureate, American College of Cardiology
2003-Present Physician / President Cardiac Center of Texas, P.A. McKinney, Texas
February 2013 - Present Co-Director Department of Palliative Care at Medical Center of Plano
2007-Present Co-Director Department of Peripheral Vascular Disease at Medical Center of Plano
November 2010 – Present Medical Director Preventive Medicine Department at Medical Center of Plano
Page 1 of 7 M. Akram Khan, MD, FACC, FSCAI July 2009 Founding Member IRB Committee at The Medical Center of Plano
2000-Present Principal Investigator NORTH DALLAS RESEARCH ASSOCIATES McKinney, Texas
2005, 2002, 2001, 2000, 1999 Chief of Cardiology Dept. Medical Center of McKinney/North Central Medical Center McKinney, Texas
2002-2004 Department Chair of Medicine Presbyterian Hospital of Allen Allen, Texas
2004 Peer Review Committee Member North Central Medical Center Hospital McKinney, Texas
2004 Vice-Chief of Cardiology North Central Medical Center Hospital McKinney, Texas
2002 Pharmacy & Therapeutics Committee Member Medical Center of Plano Plano, Texas
2002 Member Cardiovascular Performance & Improvement Team North Central Medical Center Hospital McKinney, Texas
2002-2003 Physician / Vice President Cardiovascular Physicians of North Texas, P.A. McKinney, Texas
1997-2002 Director of McKinney Clinic CPR / HeartPlace McKinney, Texas
2003 Fellow, Society for Cardiac Angiography & Interventions
1999-2003 Director of Cardiac Catheterization Lab North Central Medical Center McKinney, Texas
1992-93 Chief Medical Resident Wayne State University Medical Center Detroit, Michigan
Page 2 of 7 M. Akram Khan, MD, FACC, FSCAI 1999 Fellow, American College of Cardiology
BOARD CERTIFICATION(S): 2013 Diplomat in Phlebology American Board of Venous and Lymphatic Medicine
2012 Diplomat in Hospice and Palliative Medicine American Board of Internal Medicine
2000 Diplomat in Interventional Cardiology American Board of Internal Medicine – Recertification 2012
1998 Diplomat in Cardiovascular Disease American Board of Internal Medicine – Recertification 2009
1993 - 2008 Diplomat in Internal Medicine American Board of Internal Medicine
OTHER CERTIFICATION: 2011 Certified Clinical Research Professional Society of Clinical Research Associates
STATE LICENSURE(S): Licensed Physician, State of Texas
MEMBERSHIPS: American College of Phlebology American Academy of Hospice and Palliative Medicine Society of Clinical Research Associates Society of Cardiovascular Computed Tomography – Level 2 Accredited Society for Cardiovascular Angiography & Interventions Wyeth Pharmaceuticals Visiting Speakers Bureau Forest Pharmaceuticals Visiting Speakers Bureau Medical Group Management Association Academy of Physicians in Clinical Research Association of Clinical Research Professionals International Society of Endovascular Specialists Outpatient Endovascular and Interventional Society American College of Cardiology American Heart Association American College of Physicians Texas Medical Association Collin-Fannin County Medical Society Society for Women’s Health Research
Page 3 of 7 M. Akram Khan, MD, FACC, FSCAI HONORS: First in Undergraduate School – Gold Medallist Among top 1% on all professional exams Federal Government Merit Scholarship Pakistan Govt. Scholarship for Studying Medicine Abroad
PUBLICATIONS:
1. Khan, MA, Granda J. An atypical case of pituitary apoplexy. Abstract presented at 1991 Annual Session. ACP, Michigan Chapter
2. Spears, JR, Yellayi SS, Khan MA, Promm B. Effects of thermal exposure on binding of heparin in vivo to the arterial wall and to clot and on the chronic angiographic luminal responses to local application of a heparin film during angioplasty in an in view rabbit model. Lasers in Surgery Medicine. 1994;14:329-346.
3. Khan MA, Gerber TL, Anwar A. Percutaneous interventions for significant narrowings in saphenous vein aortocoronary conduits. Baylor University Medical Center Proceedings. 1995;5:19-25.
4. Khan MA, Gerber TX, Schreibfeder MM, Bret JR, Donsky MS, Leonard BM, Solis RM, Anwar A. The Elderly and Angioplasty: Does Gender Affect Outcome? American Journal Ger Cardiology. 1996;5(2):55.
ONGOING RESEARCH PROJECTS:
DAPT: A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiv eness and Safety of 12 Versus 30 Months of Dual Anti-platelet Therapy in Subjects Underg oing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal St ent Placement for the Treatment of Coronary Artery Lesions.
CELESTIAL: Post Approval Registry: Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar Post Approval Registry.
GALAXY Registry: Long-term Evaluation of the Linox Family ICD Leads Registry.
PROMISE: PROspective Multicenter Imaging Study for Evaluation of Chest Pain
1160.128: A prospective, open label study evaluating the efficacy of two management strate gies (pantoprazole 40 mg q.a.m. and taking Pradaxa with food (within 30 minutes after a m eal) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa 150m g b.i.d for the prevention of stroke and systemic embolism in patients with non-valvular atr ial fibrillation)
LIGHT STUDY: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Ass essing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight an
Page 4 of 7 M. Akram Khan, MD, FACC, FSCAI d Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion S R
CANTOS TRIAL: A randomized, double-blind, placebo-controlled, event driven trial of qu arterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events a mong stable post-myocardial infarction patients with elevated hsCRP.
EUCLID: A randomized, double-blind, parallel group, multicentre phase IIIb study to com pare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial i nfarction and ischaemic stroke in patients with established Peripheral Artery Disease
BIOFLEX-I: The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-ex panding Astron and Pulsar Stents.
BIOHELIX: The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy C obalt-Chromium, Bare-Metal Stent
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery
PRIOR RESEACH PROJECTS: Sub-Investigator Micardis Community Access Trial (MICCAT) Investigator Hyperlipidemia Study with Mayo Physician Alliance for Clinical Trials Investigator Hypertension and Hyperlipidemia Study Investigator Hypertension Study Investigator Hyperlipidemia Study
A Randomized, Double-Blind, Placebo- Controlled, Multicenter, Parallel-Arm Study to Assess the Long-Term Effects of XXX Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease, 2003.
Effect of XXX Vs Placebo on a Background of Standard Care Including Aspirin, in Maintaining the Patency of Lower Limb Arteries After Angioplasty, 2003
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Forced Titration, Comparison of XXX (XXX 80mg/XXX 25mg) Versus YYY (YYY 160mg/ YYY25mg) using Seated Trough Cuff Blood Pressure in Patients with Stage 1 and Stage 2 Hypertension, 2003
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of XXX in the Treatment of Patients with Type 2 Diabetes Mellitus, 2003
A Placebo-Controlled Trial of XXX Added to Standard Therapy in African American Heart Failure, 2003
Page 5 of 7 M. Akram Khan, MD, FACC, FSCAI A Dose Response of XXX ER/YYY on Peak Walking Time (PWT) in Patients with Intermittent Claudication, 2003
An open-Label, Comparative Efficacy Evaluation of Lipids Levels when Treated with XXX and YYY or Other Lipid-Modifying Therapies, 2004
A Double-Blind, Randomized, Comparator-Controlled Study in Subjects with Type 2 Diabetes Mellitus Comparing the Effects of XXX HCL Versus YYY on the Rate of Progression of Coronary Atheroscelrotic Disease as Measured by Intravascular Ultrasound, 2004.
The Effect of XXX ER/YYY on Peak Walking Time in Patients with Intermittent Claudication, 2004
A phase 3 double blind randomized multisite trial of the efficacy, safety and tolerability of the fixed combination XXX/XXX administered orally, once daily for 12 months compared to XXX alone titrated based on NCEP ATP-III LDL-C goals in subjects with Fredrickson Types IIA and IIB Dyslipidemias, 2005
User Versus Tech Study Using the CoaguChek XS Meter with CoaguChek XS System PT Tests, 2005
A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of XXX400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (AF/AFL), 2005
A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of XXX 50 MG, 100 MG or Placebo When Co-Administered with XXX 10 MG or 20 MG in Subjects with Primary Hypercholesterolemia, 2005
An 8-Week, Randomized, Double-Blind, Parallel Group, Multi-Center, Placebo and Active Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of XXX (150 Mg and 300 Mg) Administered Alone and in Combination with XXX (160 Mg and 320 Mg) in Patients with Hypertension, 2006
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 4 x 4 Factorial Design to Evaluate XXX 20, 40 and 80 Mg Tablets in Combination with XXX 2.5, 5 and 10 Mg Capsules After Eight Weeks of Treatment in Patients with Stage I or II hypertension, With an ABPM Sub-Study, 2006
A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of XXX and XXX Combination Therapy to XXX and XXX Monotherapy in Subjects with Mixed Dyslipidemia, 2006
A Long Term, Open-Label, Safety Extension Study of the Combination of XXX and XXX Therapy for Subjects with Mixed Dyslipidemia, 2006
Page 6 of 7 M. Akram Khan, MD, FACC, FSCAI A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of XXX, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease, 2006
Randomized Evaluation of Long Term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of XXX with Open Label XXX for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial, 2006
Sub-Investigator Micardis Community Access Trial (MICCAT) Investigator Hyperlipidemia Study with Mayo Physician Alliance for Clinical Trials Investigator Hypertension and Hyperlipidemia Study Investigator Hypertension Study Investigator Hyperlipidemia Study
A Randomized, Double-Blind, Placebo- Controlled, Multicenter, Parallel-Arm Study to Assess the Long-Term Effects of XXX Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease, 2003.
Effect of XXX Vs Placebo on a Background of Standard Care Including Aspirin, in Maintaining the Patency of Lower Limb Arteries After Angioplasty, 2003
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Forced Titration, Comparison of XXX (XXX 80mg/XXX 25mg) Versus YYY (YYY 160mg/ YYY25mg) using Seated Trough Cuff Blood Pressure in Patients with Stage 1 and Stage 2 Hypertension, 2003
A Multi-center, Double-Blind, Placebo-Controlled, Randomized Study of the Safety of XXX in the Treatment of Patients with Type 2 Diabetes Mellitus, 2003
A Placebo-Controlled Trial of XXX Added to Standard Therapy in African American Heart Failure, 2003
A Dose Response of XXX ER/YYY on Peak Walking Time (PWT) in Patients with Intermittent Claudication, 2003
REFERENCES: Available upon request.
Page 7 of 7 M. Akram Khan, MD, FACC, FSCAI